Publication on the Site In accordance with Rule 26.1 of the Code, a copy of this notice (subject to certain restrictions regarding persons residing in restricted jurisdictions) will be made available on Takeda`s website in www.takeda.com/investors/offer-for-shire no later than 12 noon (London time) on the working day following the date of this communication. The content of the website referred to in this communication is not part of this notice and is not part of this notice. Takeda (media – excluding Japan) Elissa JohnsenElissa.Johnsen@takeda.com+1 312 285 3203 Tsuyoshi TadaTsuyoshi.Tada@takeda.com+1 617 551 2933 In accordance with Rule 26 of the Municipal Code on Takeovers and Mergers publishes a copy of the JBIC loan on the Takeda website and www.takeda.com/investors/offer-for-shire can be viewed below on the Takeda website no later than 12:00 (London time). Please note that the acquisition remains subject to certain conditions, including the agreement of the shareholders of both companies. Takeda (Media – inside Japan) Kazumi Kobayashikazumi.email@example.com+81 3 3278 2095 Takeda (Investor Relations) Takashi Okubotakeda.firstname.lastname@example.org+81 3 3278 2306 If two or more act jointly on the basis of a formal or informal agreement or understanding, to acquire or control a stake in relevant securities of a company or stock exchange offeror, they are considered a single person within the meaning of Rule 8.3 About Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited (EST: 4502) is a global pharmaceutical company focused on research and development, working to improve the health and future of patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterological and neuroscientific fields, as well as vaccines. Takeda leads research and development, both internally and with partners, to stay at the forefront of innovation. Innovative products, particularly in oncology and gastroenterology, as well as Takeda`s presence in emerging countries, are currently driving Takeda`s growth.